Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer.

Camblin AJ, Pace EA, Adams S, Curley MD, Rimkunas V, Nie L, Tan G, Bloom T, Iadevaia S, Baum J, Minx C, Czibere A, Louis CU, Drummond DC, Nielsen UB, Schoeberl B, Pipas JM, Straubinger RM, Askoxylakis V, Lugovskoy AA.

Clin Cancer Res. 2018 Jun 15;24(12):2873-2885. doi: 10.1158/1078-0432.CCR-17-2262. Epub 2018 Mar 16.

2.

Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121).

Schoeberl B, Kudla A, Masson K, Kalra A, Curley M, Finn G, Pace E, Harms B, Kim J, Kearns J, Fulgham A, Burenkova O, Grantcharova V, Yarar D, Paragas V, Fitzgerald J, Wainszelbaum M, West K, Mathews S, Nering R, Adiwijaya B, Garcia G, Kubasek B, Moyo V, Czibere A, Nielsen UB, MacBeath G.

NPJ Syst Biol Appl. 2017 Jan 5;3:16034. doi: 10.1038/npjsba.2016.34. eCollection 2017. Review.

3.

Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer.

Liu JF, Ray-Coquard I, Selle F, Poveda AM, Cibula D, Hirte H, Hilpert F, Raspagliesi F, Gladieff L, Harter P, Siena S, Del Campo JM, Tabah-Fisch I, Pearlberg J, Moyo V, Riahi K, Nering R, Kubasek W, Adiwijaya B, Czibere A, Naumann RW, Coleman RL, Vergote I, MacBeath G, Pujade-Lauraine E.

J Clin Oncol. 2016 Dec 20;34(36):4345-4353. Epub 2016 Oct 23.

4.

A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan.

Cleary JM, McRee AJ, Shapiro GI, Tolaney SM, O'Neil BH, Kearns JD, Mathews S, Nering R, MacBeath G, Czibere A, Sharma S, Korn WM.

Invest New Drugs. 2017 Feb;35(1):68-78. doi: 10.1007/s10637-016-0399-7. Epub 2016 Nov 16.

PMID:
27853996
5.

Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy.

Zohren F, Bruns I, Pechtel S, Schroeder T, Fenk R, Czibere A, Maschmeyer G, Kofahl-Krause D, Niederle N, Heil G, Losem C, Welslau M, Brugger W, Germing U, Kronenwett R, Barth J, Rummel MJ, Haas R, Kobbe G.

Blood. 2015 Sep 17;126(12):1407-14. doi: 10.1182/blood-2015-03-630012. Epub 2015 Aug 3.

PMID:
26239087
6.

Deep serum discoveries: SDF-1α and HSA fragments in myelodysplastic syndromes.

Fröbel J, Hartwig S, Jourdain S, Fischer JC, Zilkens C, Kündgen A, Suckau D, Germing U, Czibere A, Lehr S.

Am J Hematol. 2015 Sep;90(9):E185-7. doi: 10.1002/ajh.24070. Epub 2015 Jul 27. No abstract available.

7.

Treatment of chronic myelogenous leukemia by blocking cytokine alterations found in normal stem and progenitor cells.

Welner RS, Amabile G, Bararia D, Czibere A, Yang H, Zhang H, Pontes LL, Ye M, Levantini E, Di Ruscio A, Martinelli G, Tenen DG.

Cancer Cell. 2015 May 11;27(5):671-81. doi: 10.1016/j.ccell.2015.04.004.

8.

Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions--a retrospective multicenter analysis from the German Cooperative Transplant Study Group.

Schroeder T, Rachlis E, Bug G, Stelljes M, Klein S, Steckel NK, Wolf D, Ringhoffer M, Czibere A, Nachtkamp K, Dienst A, Kondakci M, Stadler M, Platzbecker U, Uharek L, Luft T, Fenk R, Germing U, Bornhäuser M, Kröger N, Beelen DW, Haas R, Kobbe G.

Biol Blood Marrow Transplant. 2015 Apr;21(4):653-60. doi: 10.1016/j.bbmt.2014.12.016. Epub 2014 Dec 23.

9.

The tissue inhibitor of metalloproteinases-1 improves migration and adhesion of hematopoietic stem and progenitor cells.

Wilk CM, Schildberg FA, Lauterbach MA, Cadeddu RP, Fröbel J, Westphal V, Tolba RH, Hell SW, Czibere A, Bruns I, Haas R.

Exp Hematol. 2013 Sep;41(9):823-831.e2. doi: 10.1016/j.exphem.2013.04.010. Epub 2013 May 6.

PMID:
23660069
10.

C/EBPα is required for development of dendritic cell progenitors.

Welner RS, Bararia D, Amabile G, Czibere A, Benoukraf T, Bach C, Wansa KD, Ye M, Zhang H, Iino T, Hetherington CJ, Akashi K, Tenen DG.

Blood. 2013 May 16;121(20):4073-81. doi: 10.1182/blood-2012-10-463448. Epub 2013 Apr 1.

11.

Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation.

Schroeder T, Fröbel J, Cadeddu RP, Czibere A, Dienst A, Platzbecker U, Bug G, Uharek L, Fenk R, Germing U, Kröger N, Haas R, Kobbe G.

Leukemia. 2013 Sep;27(9):1910-3. doi: 10.1038/leu.2013.64. Epub 2013 Mar 1. No abstract available.

PMID:
23519388
12.

Platelet proteome analysis reveals integrin-dependent aggregation defects in patients with myelodysplastic syndromes.

Fröbel J, Cadeddu RP, Hartwig S, Bruns I, Wilk CM, Kündgen A, Fischer JC, Schroeder T, Steidl UG, Germing U, Lehr S, Haas R, Czibere A.

Mol Cell Proteomics. 2013 May;12(5):1272-80. doi: 10.1074/mcp.M112.023168. Epub 2013 Feb 4.

13.

Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation.

Schroeder T, Czibere A, Platzbecker U, Bug G, Uharek L, Luft T, Giagounidis A, Zohren F, Bruns I, Wolschke C, Rieger K, Fenk R, Germing U, Haas R, Kröger N, Kobbe G.

Leukemia. 2013 Jun;27(6):1229-35. doi: 10.1038/leu.2013.7. Epub 2013 Jan 14.

PMID:
23314834
14.

NSAIDs induce apoptosis in nonproliferating ovarian cancer cells and inhibit tumor growth in vivo.

Duncan K, Uwimpuhwe H, Czibere A, Sarkar D, Libermann TA, Fisher PB, Zerbini LF.

IUBMB Life. 2012 Jul;64(7):636-43. doi: 10.1002/iub.1035. Epub 2012 May 11.

15.

Multiple myeloma-related deregulation of bone marrow-derived CD34(+) hematopoietic stem and progenitor cells.

Bruns I, Cadeddu RP, Brueckmann I, Fröbel J, Geyh S, Büst S, Fischer JC, Roels F, Wilk CM, Schildberg FA, Hünerlitürkoglu AN, Zilkens C, Jäger M, Steidl U, Zohren F, Fenk R, Kobbe G, Brors B, Czibere A, Schroeder T, Trumpp A, Haas R.

Blood. 2012 Sep 27;120(13):2620-30. Epub 2012 Apr 18.

16.

Therapy-related myeloid neoplasms following treatment with radioiodine.

Schroeder T, Kuendgen A, Kayser S, Kröger N, Braulke F, Platzbecker U, Klärner V, Zohren F, Haase D, Stadler M, Schlenk R, Czibere AG, Bruns I, Fenk R, Gattermann N, Haas R, Kobbe G, Germing U.

Haematologica. 2012 Feb;97(2):206-12. doi: 10.3324/haematol.2011.049114. Epub 2011 Oct 11.

17.

Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.

Saure C, Schroeder T, Zohren F, Groten A, Bruns I, Czibere A, Galonska L, Kondakci M, Weigelt C, Fenk R, Germing U, Haas R, Kobbe G.

Biol Blood Marrow Transplant. 2012 Mar;18(3):466-72. doi: 10.1016/j.bbmt.2011.09.006. Epub 2011 Sep 29.

18.

Combinatorial effect of non-steroidal anti-inflammatory drugs and NF-κB inhibitors in ovarian cancer therapy.

Zerbini LF, Tamura RE, Correa RG, Czibere A, Cordeiro J, Bhasin M, Simabuco FM, Wang Y, Gu X, Li L, Sarkar D, Zhou JR, Fisher PB, Libermann TA.

PLoS One. 2011;6(9):e24285. doi: 10.1371/journal.pone.0024285. Epub 2011 Sep 12.

19.

The non-steroidal anti-inflammatory drugs Sulindac sulfide and Diclofenac induce apoptosis and differentiation in human acute myeloid leukemia cells through an AP-1 dependent pathway.

Singh R, Cadeddu RP, Fröbel J, Wilk CM, Bruns I, Zerbini LF, Prenzel T, Hartwig S, Brünnert D, Schroeder T, Lehr S, Haas R, Czibere A.

Apoptosis. 2011 Sep;16(9):889-901. doi: 10.1007/s10495-011-0624-y.

PMID:
21739277
20.

JunD-mediated repression of GADD45α and γ regulates escape from cell death in prostate cancer.

Zerbini LF, de Vasconcellos JF, Czibere A, Wang Y, Paccez JD, Gu X, Zhou JR, Libermann TA.

Cell Cycle. 2011 Aug 1;10(15):2583-91. Epub 2011 Aug 1.

21.

The novel compound OSI-461 induces apoptosis and growth arrest in human acute myeloid leukemia cells.

Singh R, Fröbel J, Cadeddu RP, Bruns I, Schroeder T, Brünnert D, Wilk CM, Zerbini LF, Haas R, Czibere A.

Ann Hematol. 2012 Feb;91(2):173-81. doi: 10.1007/s00277-011-1282-4. Epub 2011 Jun 30.

PMID:
21717102
22.

Sorafenib treatment in 13 patients with acute myeloid leukemia and activating FLT3 mutations in combination with chemotherapy or as monotherapy.

Schroeder T, Zohren F, Saure C, Bruns I, Czibere A, Safaian NN, Fenk R, Haas R, Kobbe G.

Acta Haematol. 2010;124(3):153-9. doi: 10.1159/000320173. Epub 2010 Oct 11. No abstract available.

PMID:
20938170
23.

ProteoMiner™ and SELDI-TOF-MS: a robust and highly reproducible combination for biomarker discovery from whole blood serum.

Fröbel J, Hartwig S, Passlack W, Eckel J, Haas R, Czibere A, Lehr S.

Arch Physiol Biochem. 2010 Oct-Dec;116(4-5):174-80. doi: 10.3109/13813455.2010.501082. Epub 2010 Jul 22.

PMID:
20662595
24.

Tacrolimus and mycofenolate mofetil as GvHD prophylaxis following nonmyeloablative conditioning and unrelated hematopoietic SCT for adult patients with advanced hematologic diseases.

Zohren F, Schroeder T, Czibere A, Fenk R, Bruns I, Kondakci M, Saure C, Haas R, Kobbe G.

Bone Marrow Transplant. 2011 May;46(5):747-55. doi: 10.1038/bmt.2010.167. Epub 2010 Jul 26.

PMID:
20661230
25.

The Mexican way: a feasible approach to avoid DMSO toxicity.

Schroeder T, Fenk R, Saure C, Czibere A, Bruns I, Zohren F, Haas R, Kobbe G.

Bone Marrow Transplant. 2011 Mar;46(3):469-71. doi: 10.1038/bmt.2010.140. Epub 2010 Jun 14. No abstract available.

PMID:
20548338
26.

A 3-day short course of palifermin before HDT reduces toxicity and need for supportive care after autologous blood stem-cell transplantation in patients with multiple myeloma.

Kobbe G, Bruns I, Schroeder T, Czibere A, Warnecke J, Hieronimus N, Safaian N, Kondakci M, Saure C, Germing U, Haas R, Fenk R.

Ann Oncol. 2010 Sep;21(9):1898-904. doi: 10.1093/annonc/mdq059. Epub 2010 Mar 16.

PMID:
20233744
27.

Bendamustine in patients with relapsed or refractory multiple myeloma.

Michael M, Bruns I, Bölke E, Zohren F, Czibere A, Safaian NN, Neumann F, Haas R, Kobbe G, Fenk R.

Eur J Med Res. 2010 Jan 29;15(1):13-9.

28.

Mass spectrometry-based proteomics and its potential use in haematological research.

Fröbel J, Lehr S, Haas R, Czibere A.

Arch Physiol Biochem. 2009 Dec;115(5):286-97. doi: 10.3109/13813450903428086. Review.

PMID:
19916740
29.

5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis.

Czibere A, Bruns I, Kröger N, Platzbecker U, Lind J, Zohren F, Fenk R, Germing U, Schröder T, Gräf T, Haas R, Kobbe G.

Bone Marrow Transplant. 2010 May;45(5):872-6. doi: 10.1038/bmt.2009.266. Epub 2009 Oct 12.

PMID:
19820729
30.

Low RPS14 expression is common in myelodysplastic syndromes without 5q- aberration and defines a subgroup of patients with prolonged survival.

Czibere A, Bruns I, Junge B, Singh R, Kobbe G, Haas R, Germing U.

Haematologica. 2009 Oct;94(10):1453-5. doi: 10.3324/haematol.2009.008508.

31.

Combinatorial hexapeptide ligand libraries (ProteoMiner): an innovative fractionation tool for differential quantitative clinical proteomics.

Hartwig S, Czibere A, Kotzka J, Passlack W, Haas R, Eckel J, Lehr S.

Arch Physiol Biochem. 2009 Jul;115(3):155-60. doi: 10.1080/13813450903154224.

PMID:
19604127
32.

Fludarabine, amsacrine, high-dose cytarabine and 12 Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia.

Zohren F, Czibere A, Bruns I, Fenk R, Schroeder T, Gräf T, Haas R, Kobbe G.

Bone Marrow Transplant. 2009 Dec;44(12):785-92. doi: 10.1038/bmt.2009.83. Epub 2009 May 11.

PMID:
19430496
33.

Meningioma 1 gene is differentially expressed in CD34 positive cells from bone marrow of patients with myelodysplastic syndromes with the highest expression in refractory anemia with excess of blasts and secondary acute myeloid leukemia.

Schroeder T, Czibere A, Zohren F, Aivado M, Gattermann N, Germing U, Haas R.

Leuk Lymphoma. 2009 Jun;50(6):1043-6. doi: 10.1080/10428190902913591. No abstract available.

PMID:
19391034
34.

Pegfilgrastim for PBSC mobilization and autologous haematopoietic SCT.

Kobbe G, Bruns I, Fenk R, Czibere A, Haas R.

Bone Marrow Transplant. 2009 May;43(9):669-77. doi: 10.1038/bmt.2009.59. Epub 2009 Mar 23. Review.

PMID:
19308043
35.

The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence.

Bruns I, Czibere A, Fischer JC, Roels F, Cadeddu RP, Buest S, Bruennert D, Huenerlituerkoglu AN, Stoecklein NH, Singh R, Zerbini LF, Jäger M, Kobbe G, Gattermann N, Kronenwett R, Brors B, Haas R.

Leukemia. 2009 May;23(5):892-9. doi: 10.1038/leu.2008.392. Epub 2009 Jan 22.

PMID:
19158832
36.

Differential gene expression of bone marrow-derived CD34+ cells is associated with survival of patients suffering from myelodysplastic syndrome.

Prall WC, Czibere A, Grall F, Spentzos D, Steidl U, Giagounidis AAN, Kuendgen A, Otu H, Rong A, Libermann TA, Germing U, Gattermann N, Haas R, Aivado M.

Int J Hematol. 2009 Mar;89(2):173-187. doi: 10.1007/s12185-008-0242-9. Epub 2009 Jan 20.

PMID:
19152102
37.

Early in vivo changes of the transcriptome in Philadelphia chromosome-positive CD34+ cells from patients with chronic myelogenous leukaemia following imatinib therapy.

Bruennert D, Czibere A, Bruns I, Kronenwett R, Gattermann N, Haas R, Neumann F.

Leukemia. 2009 May;23(5):983-5. doi: 10.1038/leu.2008.337. Epub 2008 Dec 4. No abstract available.

PMID:
19052557
38.

Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia.

Safaian NN, Czibere A, Bruns I, Fenk R, Reinecke P, Dienst A, Haas R, Kobbe G.

Leuk Res. 2009 Feb;33(2):348-50. doi: 10.1016/j.leukres.2008.04.017. Epub 2008 Jun 24.

PMID:
18573526
39.

Dexamethasone modulates BMP-2 effects on mesenchymal stem cells in vitro.

Jäger M, Fischer J, Dohrn W, Li X, Ayers DC, Czibere A, Prall WC, Lensing-Höhn S, Krauspe R.

J Orthop Res. 2008 Nov;26(11):1440-8. doi: 10.1002/jor.20565.

40.

Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor.

Bruns I, Steidl U, Fischer JC, Czibere A, Kobbe G, Raschke S, Singh R, Fenk R, Rosskopf M, Pechtel S, von Haeseler A, Wernet P, Tenen DG, Haas R, Kronenwett R.

Haematologica. 2008 Mar;93(3):347-55. doi: 10.3324/haematol.12081. Epub 2008 Feb 11.

41.

Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma.

Fenk R, Michael M, Zohren F, Graef T, Czibere A, Bruns I, Neumann F, Fenk B, Haas R, Kobbe G.

Leuk Lymphoma. 2007 Dec;48(12):2345-51.

PMID:
18067009
42.

Monocyte derived dendritic cells generated by IFN-alpha acquire mature dendritic and natural killer cell properties as shown by gene expression analysis.

Korthals M, Safaian N, Kronenwett R, Maihöfer D, Schott M, Papewalis C, Diaz Blanco E, Winter M, Czibere A, Haas R, Kobbe G, Fenk R.

J Transl Med. 2007 Sep 25;5:46.

43.

Age-related transcription levels of KU70, MGST1 and BIK in CD34+ hematopoietic stem and progenitor cells.

Prall WC, Czibere A, Jäger M, Spentzos D, Libermann TA, Gattermann N, Haas R, Aivado M.

Mech Ageing Dev. 2007 Sep;128(9):503-10. Epub 2007 Jul 4.

PMID:
17714764
44.

Treatment of severe hemorrhagic cystitis after allogeneic stem cell transplantation with palifermin, a recombinant human keratinocyte growth factor.

Czibere A, Bruns I, Graef T, Fenk R, Zohren F, Safaian N, Mueller M, Haas R, Kobbe G.

Biol Blood Marrow Transplant. 2007 Jul;13(7):872-4. Epub 2007 May 23. No abstract available.

45.

Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease.

Aivado M, Spentzos D, Germing U, Alterovitz G, Meng XY, Grall F, Giagounidis AA, Klement G, Steidl U, Otu HH, Czibere A, Prall WC, Iking-Konert C, Shayne M, Ramoni MF, Gattermann N, Haas R, Mitsiades CS, Fung ET, Libermann TA.

Proc Natl Acad Sci U S A. 2007 Jan 23;104(4):1307-12. Epub 2007 Jan 12.

46.

A novel pathway involving melanoma differentiation associated gene-7/interleukin-24 mediates nonsteroidal anti-inflammatory drug-induced apoptosis and growth arrest of cancer cells.

Zerbini LF, Czibere A, Wang Y, Correa RG, Otu H, Joseph M, Takayasu Y, Silver M, Gu X, Ruchusatsawat K, Li L, Sarkar D, Zhou JR, Fisher PB, Libermann TA.

Cancer Res. 2006 Dec 15;66(24):11922-31.

47.

Perspectives of proteomics in acute myeloid leukemia.

Czibere A, Grall F, Aivado M.

Expert Rev Anticancer Ther. 2006 Nov;6(11):1663-75. Review.

PMID:
17134369
48.

Exisulind induces apoptosis in advanced myelodysplastic syndrome (MDS) and acute myeloid leukaemia/MDS.

Czibere A, Prall WC, Zerbini LF, Jäger M, Kobbe G, Knipp S, Libermann TA, Haas R, Aivado M.

Br J Haematol. 2006 Nov;135(3):355-7. Epub 2006 Sep 15.

PMID:
16978222
49.

X-linked sideroblastic anemia associated with a novel ALAS2 mutation and unfortunate skewed X-chromosome inactivation patterns.

Aivado M, Gattermann N, Rong A, Giagounidis AA, Prall WC, Czibere A, Hildebrandt B, Haas R, Bottomley SS.

Blood Cells Mol Dis. 2006 Jul-Aug;37(1):40-5. Epub 2006 Jun 2.

PMID:
16735131
50.

The nonsteroidal anti-inflammatory drug Exisulind selectively induces apoptosis via JNK in secondary acute myeloid leukemia after myelodysplastic syndrome.

Czibere A, Prall WC, Zerbini LF, Grall F, Craigie EC, Ulrich SD, Giagounidis AA, Haas R, Libermann TA, Aivado M.

Cell Cycle. 2005 Jun;4(6):812-7. Epub 2005 Jun 8.

PMID:
15970671

Supplemental Content

Loading ...
Support Center